LEVODOPA

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H11NO4
Molecular Weight	197.1879
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O

InChI

InChIKey=WTDRDQBEARUVNC-LURJTMIESA-N

InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C9H11NO4
Molecular Weight	197.1879
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21080185
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23948989 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021485s20lbl.pdf

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been widely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D1 receptor 101 Target ID: CHEMBL2056 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18851961	Agonist 2662
Dopamine receptor 58 Target ID: CHEMBL2096905 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017555s056s068s071lbl.pdf	Agonist 2662

Conditions

Condition	Modality	Targets	Highest Phase	Product
Parkinson's disease 225 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021485s20lbl.pdf	Primary		Approved 8360	Stalevo Approved Use Stalevo® (carbidopa, levodopa and entacapone) is indicated to treat patients with idiopathic Parkinson’s disease. Launch Date 1.0552032E12

C_max

Value	Dose	Co-administered	Analyte	Population
0.946 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22549097	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: CARBIDOPA, DL-	CARBIDOPA, DL-	LEVODOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
84.8 μg × min/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22549097	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: CARBIDOPA, DL-	CARBIDOPA, DL-	LEVODOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
78.7 min EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/22549097	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: CARBIDOPA, DL-	CARBIDOPA, DL-	LEVODOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
80% DRUG LABEL https://www.drugs.com/monograph/levodopa-carbidopa.html			LEVODOPA plasma	Homo sapiens

Doses

Dose	Population	Adverse events
3 g 1 times / day multiple, oral Dose: 3 g, 1 times / day Route: oral Route: multiple Dose: 3 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5550880	unhealthy, 54 years n = 1 Health Status: unhealthy Condition: idiopathic Parkinson's disease Age Group: 54 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/5550880	Disc. AE: Alopecia... AEs leading to discontinuation/dose reduction: Alopecia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/5550880
420 mg 1 times / day multiple, respiratory Recommended Dose: 420 mg, 1 times / day Route: respiratory Route: multiple Dose: 420 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209184s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209184s000lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209184s000lbl.pdf
84 mg 2 times / day multiple, respiratory Recommended Dose: 84 mg, 2 times / day Route: respiratory Route: multiple Dose: 84 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209184s000lbl.pdf	unhealthy, adult n = 114 Health Status: unhealthy Condition: Parkinson’s disease Age Group: adult Population Size: 114 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209184s000lbl.pdf	Disc. AE: Cough... AEs leading to discontinuation/dose reduction: Cough (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209184s000lbl.pdf
0.51 mg/kg 3 times / day steady, oral Dose: 0.51 mg/kg, 3 times / day Route: oral Route: steady Dose: 0.51 mg/kg, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01176435	unhealthy, child\|adult n = 15 Health Status: unhealthy Condition: Vision Impairment Age Group: child\|adult Population Size: 15 Sources: https://clinicaltrials.gov/ct2/show/NCT01176435	Other AEs: Headache, Nausea... Other AEs: Headache (below serious, 2 patients) Nausea (below serious, 2 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01176435
0.76 mg/kg 3 times / day steady, oral Dose: 0.76 mg/kg, 3 times / day Route: oral Route: steady Dose: 0.76 mg/kg, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01176435	unhealthy, child\|adult n = 15 Health Status: unhealthy Condition: Vision Impairment Age Group: child\|adult Population Size: 15 Sources: https://clinicaltrials.gov/ct2/show/NCT01176435	Other AEs: Headache, Dry mouth... Other AEs: Headache (below serious, 1 patient) Dry mouth (below serious, 2 patients) Nausea (below serious, 1 patient) Fatigue (below serious, 2 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01176435

AEs

AE	Significance	Dose	Population
Alopecia	1 patient Disc. AE	3 g 1 times / day multiple, oral Dose: 3 g, 1 times / day Route: oral Route: multiple Dose: 3 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5550880	unhealthy, 54 years n = 1 Health Status: unhealthy Condition: idiopathic Parkinson's disease Age Group: 54 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/5550880
Cough	2% Disc. AE	84 mg 2 times / day multiple, respiratory Recommended Dose: 84 mg, 2 times / day Route: respiratory Route: multiple Dose: 84 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209184s000lbl.pdf	unhealthy, adult n = 114 Health Status: unhealthy Condition: Parkinson’s disease Age Group: adult Population Size: 114 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209184s000lbl.pdf
Headache	below serious, 2 patients	0.51 mg/kg 3 times / day steady, oral Dose: 0.51 mg/kg, 3 times / day Route: oral Route: steady Dose: 0.51 mg/kg, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01176435	unhealthy, child\|adult n = 15 Health Status: unhealthy Condition: Vision Impairment Age Group: child\|adult Population Size: 15 Sources: https://clinicaltrials.gov/ct2/show/NCT01176435
Nausea	below serious, 2 patients	0.51 mg/kg 3 times / day steady, oral Dose: 0.51 mg/kg, 3 times / day Route: oral Route: steady Dose: 0.51 mg/kg, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01176435	unhealthy, child\|adult n = 15 Health Status: unhealthy Condition: Vision Impairment Age Group: child\|adult Population Size: 15 Sources: https://clinicaltrials.gov/ct2/show/NCT01176435
Headache	below serious, 1 patient	0.76 mg/kg 3 times / day steady, oral Dose: 0.76 mg/kg, 3 times / day Route: oral Route: steady Dose: 0.76 mg/kg, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01176435	unhealthy, child\|adult n = 15 Health Status: unhealthy Condition: Vision Impairment Age Group: child\|adult Population Size: 15 Sources: https://clinicaltrials.gov/ct2/show/NCT01176435
Nausea	below serious, 1 patient	0.76 mg/kg 3 times / day steady, oral Dose: 0.76 mg/kg, 3 times / day Route: oral Route: steady Dose: 0.76 mg/kg, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01176435	unhealthy, child\|adult n = 15 Health Status: unhealthy Condition: Vision Impairment Age Group: child\|adult Population Size: 15 Sources: https://clinicaltrials.gov/ct2/show/NCT01176435
Dry mouth	below serious, 2 patients	0.76 mg/kg 3 times / day steady, oral Dose: 0.76 mg/kg, 3 times / day Route: oral Route: steady Dose: 0.76 mg/kg, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01176435	unhealthy, child\|adult n = 15 Health Status: unhealthy Condition: Vision Impairment Age Group: child\|adult Population Size: 15 Sources: https://clinicaltrials.gov/ct2/show/NCT01176435
Fatigue	below serious, 2 patients	0.76 mg/kg 3 times / day steady, oral Dose: 0.76 mg/kg, 3 times / day Route: oral Route: steady Dose: 0.76 mg/kg, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01176435	unhealthy, child\|adult n = 15 Health Status: unhealthy Condition: Vision Impairment Age Group: child\|adult Population Size: 15 Sources: https://clinicaltrials.gov/ct2/show/NCT01176435

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-0948	http://www.3bsc.com/index/pro_info.php?id=41853
AA Blocks	AA0036Y3	http://www.aablocks.com/goods/Goods/detail?id=AA0036Y3
AHH Chemical co.,ltd	MB-00616	http://www.ahhchemical.com/product/MB-00616.html
AHH Chemical co.,ltd	MT-53193	http://www.ahhchemical.com/product/MT-53193.html
AHH Chemical co.,ltd	NP-1030	http://www.ahhchemical.com/product/NP-1030.html
AK Scientific, Inc. (AKSCI)	H813	http://www.aksci.com/item_detail.php?cat=H813
AK Scientific, Inc. (AKSCI)	J10404	http://www.aksci.com/item_detail.php?cat=J10404
Aaron Chemicals	AR0037PV	http://www.aaronchem.com/59-92-7
AbMole Bioscience	M3255	http://www.abmole.com/products/levodopa.html
Acadechem	ACDS-070481	http://www.acadechemical.com/product/145180
Achemtek	0104-004095	http://www.achemtek.com/59-92-7
Acorn PharmaTech	ACN-038322	http://www.acornpharmatech.com/
Acros Organics	AC167530050	https://www.fishersci.com/shop/products/3-3-4-dihydroxyphenyl-l-alanine-99-acros-organics-2/AC167530050
Acros Organics	AC167530250	https://www.fishersci.com/shop/products/3-3-4-dihydroxyphenyl-l-alanine-99-acros-organics-2/AC167530250
Acros Organics	AC167531000	https://www.fishersci.com/shop/products/3-3-4-dihydroxyphenyl-l-alanine-99-acros-organics/AC167531000
Acros Organics	AC167535000	https://www.fishersci.com/shop/products/3-3-4-dihydroxyphenyl-l-alanine-99-acros-organics/AC167535000
Alfa Aesar	A11311	https://www.alfa.com/en/catalog/A11311/
Alfa Chemistry	AP59927	https://reagents.alfa-chemistry.com/product/3-4-dihydroxy-l-phenylalanine-cas-59-92-7-13808.html
Alfa Chemistry	AP59927-A	https://reagents.alfa-chemistry.com/product/levodopa-cas-59-92-7-13809.html
Alfa Chemistry	AP59927-B	https://reagents.alfa-chemistry.com/product/levodopa-cas-59-92-7-13810.html
Angene	AGN-PC-0WADKI	http://www.angenechemical.com/productshow/AGN-PC-0WADKI.html
Anward	ANW-33396	http://www.anward.com/pro_result/10378
ApexBio Technology	A8460	http://www.apexbt.com/levodopa-22206.html
ApexBio Technology	N1648	http://www.apexbt.com/levodopa.html
Ark Pharm	AK187821	http://www.arkpharminc.com/products/59-92-7.html
Aurum Pharmatech LLC	KM0355	http://www.Aurumpharmatech.com/Product/ProductDetails/KM0355
AvaChem Scientific	3015	http://www.avachem.com/productSearch.asp?3015
Avantor Inc	101095-322	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101095-322
BioSynth	Q-201294	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-201294.html
Boerchem	BC677906	http://www.boerchem.com/?product_39610.html
BroadPharm	BP-12850	http://www.broadpharm.com/web/product.php?catalog=BP-12850
Chem Scene	CS-1945	http://www.chemscene.com/59-92-7.html
ChemFaces	CFN99800	http://www.chemfaces.com/natural/Levodopa-CFN99800.html
ChemMol	30101553	http://www.chemmol.com/chemmol/30101553.html
ChemMol	44009509	http://www.chemmol.com/chemmol/44009509.html
ChemMol	83602606	http://www.chemmol.com/chemmol/83602606.html
Chemodex	D0465	http://www.chemodex.com/products/D0465
Chemspace	CSSB00000743922	https://chem-space.com/CSSB00000743922
DC Chemicals	DCZ-030	http://www.dcchemicals.com//product_show-Levodopa.html
Enamine	Z1762772338	https://www.enaminestore.com/catalog/Z1762772338
Glentham Life Sciences	GM9724	http://www.glentham.com/products/product/GM9724/
Hairui	HR127040	http://www.hairuichem.com/en/product/59-92-7.html
Hello Bio	HB1925	https://www.hellobio.com/l-dopa.html
LGC Standards	LGCFOR0262.00	https://www.lgcstandards.com/US/en/p/LGCFOR0262.00
LGC Standards	MM0262.00	https://www.lgcstandards.com/US/en/p/MM0262.00
Lab Network	LN00235827	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00235827
MedChem Express	HY-N0304	https://www.medchemexpress.com/L-DOPA.html
OChem	3792	http://www.ocheminc.com/index.php?act=psearch&pid=59L927
Oakwood	358380	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=168845&ExtHyperLink=1
Selleck Chemicals	S1726	http://www.selleckchem.com/products/Levodopa(Sinemet).html
Sigma-Aldrich	72816_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/72816?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	BP213_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/bp213?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	L0400000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/l0400000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	D9628_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/d9628?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1361009_USP	https://www.sigmaaldrich.com/catalog/product/usp/1361009?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S054824	http://www.sinfoobiotech.com/product/1058222
Smolecule	S532941	http://www.smolecule.com/products/s532941
Smolecule	S772657	https://www.smolecule.com/products/s772657
Synthink Research Chemicals	SA31801	https://synthinkchemicals.com/product/carbidopa-ep-impurity-a/
TCI (Tokyo Chemical Industry)	D0600	http://www.tcichemicals.com/eshop/en/us/commodity/D0600/index.html
THE BioTek	bt-273342	https://www.thebiotek.com/product/inhibitors/bt-273342
Tocris	3788	https://www.tocris.com/products/l-dopa_3788
Vesino Industrial Co Ltd	VA11170	http://www.vsnchem.com/goto/product/22521/
VladaChem	VL141956	https://www.vladachem.com/product.php?products=59-92-7
VladaChem	VL162882	https://www.vladachem.com/product.php?products=59-92-7
VladaChem	VL261104-100G	https://www.vladachem.com/product.php?products=59-92-7
Watanabe Chemical Ind.	G00130	https://www.watanabechem.co.jp/en/search/details.php?code=G00130
Yuhao Chemical	LL0046	http://www.chemyuhao.com/59-92-7.html
abcr GmbH	AB110351	http://www.abcr.com/shop/en/AB110351
abcr GmbH	AB518194	http://www.abcr.com/shop/en/AB518194
eNovation Chemicals	D404611	https://www.enovationchem.com/ProductDetails.asp?ProductID=D404611
eNovation Chemicals	D954464	https://www.enovationchem.com/ProductDetails.asp?ProductID=D954464
iChemical	EBD21212	http://www.ichemical.com/products/59-92-7.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-4743781842	https://mcule.com/MCULE-4743781842/

PubMed

Title	Date	PubMed
The effects of combining carbidopa with levodopa for Parkinson's disease.	1975 Dec	1104406
Levodopa-induced postural hypotension. Treatment with fludrocortisone.	1975 Jan	1115660
[Abnormal movements induced by L-dopa. New therapeutic possibilities].	1975 Jan 25	1124379
[A case of primary brain-stem injury recovered from persistent vegetative state after L-dopa administration].	1999 Dec	10654305
Functional mapping of the human globus pallidus: contrasting effect of stimulation in the internal and external pallidum in Parkinson's disease.	2000	11068138
Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia.	2000	10858612
Preventing levodopa-induced dyskinesias.	2000 Apr	10762145
Investigating levodopa-induced dyskinesias in the parkinsonian primate.	2000 Apr	10762135
Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance.	2000 Apr	10761650
Sleep attacks and Parkinson's disease treatment.	2000 Apr 15	10776750
[Dopaminergic agonists in the treatment of Parkinson's disease].	2000 Dec	11194495
Evidence of functional somatotopy in GPi from results of pallidotomy.	2000 Dec	11099450
Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease.	2000 Dec 26	11134399
Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease.	2000 Feb	10739171
Four novel mutations in the tyrosine hydroxylase gene in patients with infantile parkinsonism.	2000 Jan	11246459
Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration.	2000 Mar	10752591
Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease.	2000 Mar	10752589
Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?	2000 May	10805339
Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks.	2000 Nov	11104192
Centrally initiated postural adjustments in parkinsonian patients on and off levodopa.	2000 Nov	11067986
[Treatment of advanced Parkinson's disease].	2000 Oct	11068447
Expression of metallothionein-III mRNA and its regulation by levodopa in the basal ganglia of hemi-parkinsonian rats.	2000 Oct 20	11065139
The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier.	2000 Oct 6	11011012
Workshop IV: drug treatment guidelines for the long-term management of Parkinson's disease.	2000 Sep	11199819
Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.	2000 Sep	11009193
Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?	2000 Sep	11009192
Adverse drug reactions to selegiline: a review of the French pharmacovigilance database.	2000 Sep-Oct	11154095
Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.	2001	11432539
Melanogenesis by tyrosinase action on 3,4-dihydroxyphenylalanine (DOPA) in the presence of polyethylene glycol: a matrix-assisted laser desorption/ionization mass spectrometric investigation.	2001	11404842
A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy.	2001	11261748
Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.	2001	11244274
High dose naltrexone for dyskinesias induced by levodopa.	2001 Apr	11254789
Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36.	2001 Apr	11254447
Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.	2001 Apr 15	11295535
SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.	2001 Aug	11400182
Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum.	2001 Feb	11207812
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.	2001 Feb	11176963
Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.	2001 Feb	11160877
Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease.	2001 Jan	11215593
SPECT imaging of the dopamine transporter in juvenile-onset dystonia.	2001 Jan 23	11160970
Biogenic aldehyde(s) derived from the action of monoamine oxidase may mediate the antidipsotropic effect of daidzin.	2001 Jan 30	11306106
Resveratrol and a novel tyrosinase in Carignan grape juice.	2001 Mar	11312883
Does stimulation of the GPi control dyskinesia by activating inhibitory axons?	2001 Mar	11295772
Effects of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) on alpha2-adrenoceptors which regulate the synthesis and release of noradrenaline in the rat brain.	2001 Mar	11245411
Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa.	2001 Mar	11222456
Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease.	2001 Mar	11181848
The effect of levodopa on vocal function in Parkinson's disease.	2001 Mar-Apr	11307045
Levodopa-induced drowsiness in healthy volunteers: results of a choice reaction time test combined with a subjective evaluation of sedation.	2001 Mar-Apr	11307043
Parkinsonism after glycine-derivate exposure.	2001 May	11391760
Speech dysfluency exacerbated by levodopa in Parkinson's disease.	2001 May	11391759

Patents

Sample Use Guides

In Vivo Use Guide

Maximum dosage in a 24-hour period is eight tablets (Stalevo 50, containing 12.5 mg of carbidopa, 50 mg of levodopa and 200 mg of entacapone; Stalevo 75, containing 18.75 mg of carbidopa, 75 mg of levodopa and 200 mg of entacapone; Stalevo 100, containing 25 mg of carbidopa, 100 mg of levodopa and 200 mg of entacapone; Stalevo 125, containing 31.25 mg of carbidopa, 125 mg of levodopa and 200 mg of entacapone; Stalevo 150, containing 37.5 mg of carbidopa, 150 mg of levodopa and 200 mg of entacapone; Stalevo 200, containing 50 mg of carbidopa, 200 mg of levodopa and 200 mg of entacapone). The optimum daily dosage must be determined by careful titration in each patient.

Route of Administration: Oral

In Vitro Use Guide

Low dose (<30 uM) Levodopa protects PC12 cells against oxidative stress which might be related to the up-regulation of CD39 and pCREB expression.

Substance Class	Chemical Created by `admin` on `Thu Jul 06 22:28:23 UTC 2023` Edited by `admin` on `Thu Jul 06 22:28:23 UTC 2023`
Record UNII	46627O600J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LEVODOPA

Official Name

English

LEVODOPA [JAN]

Common Name

English

RYTARY COMPONENT LEVODOPA

Brand Name

English

CARBILEV COMPONENT LEVODOPA

Common Name

English

levodopa [INN]

Common Name

English

LEVODOPA COMPONENT OF SINEMET

Common Name

English

V-1512

Code

English

LEVODOPA [WHO-IP]

Common Name

English

LEVODOPA [ORANGE BOOK]

Common Name

English

CORBILTA COMPONENT LEVODOPA

Brand Name

English

LEVODOPA [EMA EPAR]

Common Name

English

L-DOPA

Systematic Name

English

LEVODOPA [USP-RS]

Common Name

English

LEVODOPA COMPONENT OF DUOPA

Brand Name

English

BENDOPA

Brand Name

English

LEVODOPA COMPONENT OF STALEVO

Brand Name

English

LEVODOPA [USAN]

Common Name

English

LEVODOPA COMPONENT OF DOPASNAP

Common Name

English

LEVODOPA [USP MONOGRAPH]

Common Name

English

LEVODOPA/CARBIDOPA/ENTACAPONE ORION COMPONENT LEVODOPA

Brand Name

English

LEVODOPA COMPONENT OF CORBILTA

Brand Name

English

LEVODOPA [EP IMPURITY]

Common Name

English

STALEVO COMPONENT LEVODOPA

Brand Name

English

LEVODOPA COMPONENT OF PARCOPA

Common Name

English

LARODOPA

Brand Name

English

LEVODOPA COMPONENT OF LEVODOPA/CARBIDOPA/ENTACAPONE ORION

Brand Name

English

IPX203 COMPONENT LEVODOPA

Common Name

English

DOPAR

Brand Name

English

DUOPA COMPONENT LEVODOPA

Brand Name

English

PARCOPA COMPONENT LEVODOPA

Common Name

English

LEVODOPA [HSDB]

Common Name

English

LEVODOPA [EP MONOGRAPH]

Common Name

English

IPX-203 COMPONENT LEVODOPA

Common Name

English

LEVODOPA [MI]

Common Name

English

LEVODOPA COMPONENT OF CARBILEV

Common Name

English

DIHYDROXYPHENYLALANINE

Systematic Name

English

NSC-118381

Code

English

(-)-3-(3,4-DIHYDROXYPHENYL)-L-ALANINE

Systematic Name

English

Levodopa [WHO-DD]

Common Name

English

LEVODOPA COMPONENT OF DHIVY

Brand Name

English

DHIVY COMPONENT LEVODOPA

Brand Name

English

LEVODOPUM [WHO-IP LATIN]

Common Name

English

LEVODOPA COMPONENT OF RYTARY

Brand Name

English

L-TYROSINE, 3-HYDROXY-

Systematic Name

English

DOPASNAP COMPONENT LEVODOPA

Common Name

English

DOPA, L-

Systematic Name

English

CVT-301

Common Name

English

LEVODOPA [MART.]

Common Name

English

INBRIJA

Brand Name

English

LEVODOPA [VANDF]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QN04BA03

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

DSLD

1198 (Number of products:24)

Created by admin on Thu Jul 06 22:28:25 UTC 2023 , Edited by admin on Thu Jul 06 22:28:25 UTC 2023

WHO-ESSENTIAL MEDICINES LIST

09 (LEV/CAR)

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

EMA ASSESSMENT REPORTS

CORBILTA (AUTHORIZED: PARKINSON DISEASE)

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

EU-Orphan Drug

EU/3/01/035

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

EMA ASSESSMENT REPORTS

STALEVO (AUTHORIZED: PARKINSON DISEASE)

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

WHO-ATC

N04BA01

Created by admin on Thu Jul 06 22:28:25 UTC 2023 , Edited by admin on Thu Jul 06 22:28:25 UTC 2023

EMA ASSESSMENT REPORTS

CORBILTA (AUTHORIZED: NEURODEGENERATIVE DISEASES)

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

WHO-VATC

QN04BA02

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

WHO-ATC

N04BA03

Created by admin on Thu Jul 06 22:28:25 UTC 2023 , Edited by admin on Thu Jul 06 22:28:25 UTC 2023

WHO-VATC

QN04BA01

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

LOINC

79577-3

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

NDF-RT

N0000193220

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

LIVERTOX

NBK548734

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

FDA ORPHAN DRUG

129499

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

NDF-RT

N0000175754

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

WHO-ATC

N04BA02

Created by admin on Thu Jul 06 22:28:25 UTC 2023 , Edited by admin on Thu Jul 06 22:28:25 UTC 2023

NCI_THESAURUS

C66884

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

NDF-RT

N0000175755

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

EMA ASSESSMENT REPORTS

LEVODOPA/CARBIDOPA/ENTACAPONE ORION (AUTHORIZED: PARKINSON DISEASE)

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

EMA ASSESSMENT REPORTS

CORBILTA (AUTHORIZED: NERVOUS SYSTEM DISEASES)

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

Code System Code Type Description

PUBCHEM

6047

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

WIKIPEDIA

L-DOPA

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

LACTMED

Levodopa

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

WHO INTERNATIONAL PHARMACOPEIA

LEVODOPA

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

Description: A white or almost white, crystalline powder; odourless. Solubility: Soluble in 300 parts of water; practically insoluble in ethanol (~750 g/l) TS and ether R. Category: Antiparkinsonism drug. Storage: Levodopa should be kept in a tightly closed container.Definition: Levodopa contains not less than 98.5% and not more than 101.0% of C9H11NO4, calculated with reference to the dried substance.

MESH

D007980

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

DRUG CENTRAL

1567

Created by admin on Thu Jul 06 22:28:25 UTC 2023 , Edited by admin on Thu Jul 06 22:28:25 UTC 2023

PRIMARY

NSC

118381

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

NCI_THESAURUS

C611

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

EVMPD

SUB08468MIG

Created by admin on Thu Jul 06 22:28:25 UTC 2023 , Edited by admin on Thu Jul 06 22:28:25 UTC 2023

PRIMARY

EPA CompTox

DTXSID9023209

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

FDA UNII

46627O600J

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

ChEMBL

CHEMBL1009

Created by admin on Thu Jul 06 22:28:25 UTC 2023 , Edited by admin on Thu Jul 06 22:28:25 UTC 2023

PRIMARY

DAILYMED

46627O600J

Created by admin on Thu Jul 06 22:28:25 UTC 2023 , Edited by admin on Thu Jul 06 22:28:25 UTC 2023

PRIMARY

CHEBI

57504

Created by admin on Thu Jul 06 22:28:25 UTC 2023 , Edited by admin on Thu Jul 06 22:28:25 UTC 2023

PRIMARY

HSDB

3348

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

SMS_ID

100000085446

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

CHEBI

15765

Created by admin on Thu Jul 06 22:28:25 UTC 2023 , Edited by admin on Thu Jul 06 22:28:25 UTC 2023

PRIMARY

IUPHAR

3639

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

MERCK INDEX

M6786

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

Merck Index

INN

2651

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

ECHA (EC/EINECS)

200-445-2

Created by admin on Thu Jul 06 22:28:25 UTC 2023 , Edited by admin on Thu Jul 06 22:28:25 UTC 2023

PRIMARY

CAS

59-92-7

Created by admin on Thu Jul 06 22:28:25 UTC 2023 , Edited by admin on Thu Jul 06 22:28:25 UTC 2023

PRIMARY

RS_ITEM_NUM

1361009

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

DRUG BANK

DB01235

Created by admin on Thu Jul 06 22:28:25 UTC 2023 , Edited by admin on Thu Jul 06 22:28:25 UTC 2023

PRIMARY

RXCUI

6375

Created by admin on Thu Jul 06 22:28:26 UTC 2023 , Edited by admin on Thu Jul 06 22:28:26 UTC 2023

PRIMARY

RxNorm

Related Record Type Details


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					22Q832K2UN

CATECHOL O-METHYLTRANSFERASE

METABOLIC ENZYME -> SUBSTRATE

Amount:


					55G8SQ543S

MUCUNA PRURIENS SEED

PARENT -> CONSTITUENT ALWAYS PRESENT


					46627O600J

LEVODOPA

BASIS OF STRENGTH->SUBSTANCE

Interaction Type:

ASSAY (HPLC)

Qualification:

USP

Amount:


					46627O600J

LEVODOPA

BASIS OF STRENGTH->SUBSTANCE

Interaction Type:

ASSAY (TITRATION)

Qualification:

EP

Amount:


					54202V7DRJ

D(1A) DOPAMINE RECEPTOR

TARGET -> AGONIST

Related Record Type Details


					895X917GYE

ETILEVODOPA

PRODRUG -> METABOLITE ACTIVE

Amount:


					37NQZ0J76I

FOSLEVODOPA

PRODRUG -> METABOLITE ACTIVE


					G69RN28K8B

BISMUTH SUBDOPATE

PRODRUG -> METABOLITE ACTIVE


					M30686U4X4

MELEVODOPA

PRODRUG -> METABOLITE ACTIVE

Amount:


					VTD58H1Z2X

DOPAMINE

METABOLITE ACTIVE -> PRODRUG


					VTD58H1Z2X

DOPAMINE

METABOLITE ACTIVE -> PRODRUG

Interaction Type:

MAJOR

Amount:


					V3O7J20DWN

3-O-METHYLDOPA

METABOLITE -> PARENT

Comments:

When decarboxylation of levodopa is prevented by carbidopa, COMT becomes the major metabolizing enzyme for levodopa, catalyzing its metabolism to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD).

Amount:


					K59Z6Z8REF

3-HYDROXYBENZENEACETIC ACID

METABOLITE -> PARENT

Amount:

Related Record Type Details


					SO86T1OB2P

3-O-METHYLDOPA, DL-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					8T862R29FY

DOPA, D-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					580PK2O48O

6-HYDROXYDOPA, L-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					9HBL9XYQ8O

6-HYDROXYDOPA, DL-

PARENT -> IMPURITY

Amount:


					580PK2O48O

6-HYDROXYDOPA, L-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					42HK56048U

TYROSINE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					42HK56048U

TYROSINE

IMPURITY -> PARENT

Comments:

For the calculation of contents, multiply the peak areas by 2.2

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					SO86T1OB2P

3-O-METHYLDOPA, DL-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					GC6UEI64EC

3,4-DIMETHOXYPHENYLALANINE, L-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:

Related Record Type Details


					46627O600J

LEVODOPA

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21080185Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23948989 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021485s20lbl.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21080185
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23948989 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021485s20lbl.pdf

C_max

T_1/2

F_unbound